Indeed, the combination between standard induction therapy or hypomethylating agents and IDH inhibitors, such as ivosidenib and enasidenib, demonstrated to improve the OS and CR of AML patients by leading to the differentiation of AML cells, which became more sensitive to treatments. Here, IDH2 is linked to acute myeloid leukemia.